MAPK pathway and NIS in B-CPAP human papillary thyroid carcinoma cells treated with resveratrol

IF 2.9 4区医学 Q2 PATHOLOGY Pathology, research and practice Pub Date : 2024-10-10 DOI:10.1016/j.prp.2024.155623

Gokcen Unal Kocabas , Asli Kisim Blatti , Afig Berdeli , Ahmet Gokhan Ozgen , Banu Sarer Yurekli

{"title":"MAPK pathway and NIS in B-CPAP human papillary thyroid carcinoma cells treated with resveratrol","authors":"Gokcen Unal Kocabas , Asli Kisim Blatti , Afig Berdeli , Ahmet Gokhan Ozgen , Banu Sarer Yurekli","doi":"10.1016/j.prp.2024.155623","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Resveratrol, a herbal phytoalexin, is known to have anti-tumor effects in several tumors including thyroid cancer cells.</div></div><div><h3>Aim</h3><div>The aim of this study was to determine the effects of resveratrol on the expression of BRAF, ERK and NIS mRNA levels and protein expression in B-CPAP human thyroid papillary cancer cell line.</div></div><div><h3>Methods</h3><div>B-CPAP cells were treated with resveratrol at concentrations of 10–100 μM for 24–48–72 h. Cell viability was assessed by XTT Cell Proliferation Assay. BRAF, ERK and NIS mRNA levels were evaluated by rt-PCR method. Protein expressions were evaluated by Western Blot method.</div></div><div><h3>Results</h3><div>Resveratrol was found to inhibit cell proliferation in a time and dose dependent manner. The IC50 values of resveratrol were 18.7 μM and 56.8 μM after 48 h and 72 h respectively. Resveratrol treatment of B-CPAP cells resulted in up to 1.5-fold reduction in BRAF mRNA and up to 5.5 fold reduction in ERK mRNA levels. NIS mRNA levels showed up to 3-fold increase. Western Blot studies confirmed the rt- PCR results with a decrease in BRAF and ERK, and increase in NIS protein expressions.</div></div><div><h3>Conclusion</h3><div>This study demonstrated that resveratrol inhibits thyroid papillary carcinoma cell proliferation and reduces poor prognostic BRAF and ERK mRNA and protein expressions, while increasing NIS mRNA and protein expression suggesting a redifferentiating effect. More studies are needed to evaluate resveratrol as a novel therapeutic agent in the treatment of papillary thyroid cancer.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"263 ","pages":"Article 155623"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S034403382400534X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Resveratrol, a herbal phytoalexin, is known to have anti-tumor effects in several tumors including thyroid cancer cells.

Aim

The aim of this study was to determine the effects of resveratrol on the expression of BRAF, ERK and NIS mRNA levels and protein expression in B-CPAP human thyroid papillary cancer cell line.

Methods

B-CPAP cells were treated with resveratrol at concentrations of 10–100 μM for 24–48–72 h. Cell viability was assessed by XTT Cell Proliferation Assay. BRAF, ERK and NIS mRNA levels were evaluated by rt-PCR method. Protein expressions were evaluated by Western Blot method.

Results

Resveratrol was found to inhibit cell proliferation in a time and dose dependent manner. The IC50 values of resveratrol were 18.7 μM and 56.8 μM after 48 h and 72 h respectively. Resveratrol treatment of B-CPAP cells resulted in up to 1.5-fold reduction in BRAF mRNA and up to 5.5 fold reduction in ERK mRNA levels. NIS mRNA levels showed up to 3-fold increase. Western Blot studies confirmed the rt- PCR results with a decrease in BRAF and ERK, and increase in NIS protein expressions.

Conclusion

This study demonstrated that resveratrol inhibits thyroid papillary carcinoma cell proliferation and reduces poor prognostic BRAF and ERK mRNA and protein expressions, while increasing NIS mRNA and protein expression suggesting a redifferentiating effect. More studies are needed to evaluate resveratrol as a novel therapeutic agent in the treatment of papillary thyroid cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

白藜芦醇处理的 B-CPAP 人甲状腺乳头状癌细胞中的 MAPK 通路和 NIS

背景白藜芦醇是一种草本植物雌激素，已知它对包括甲状腺癌细胞在内的多种肿瘤具有抗肿瘤作用。用 XTT 细胞增殖试验评估细胞活力。采用 rt-PCR 方法评估 BRAF、ERK 和 NIS mRNA 水平。结果发现白藜芦醇以时间和剂量依赖的方式抑制细胞增殖。48 小时和 72 小时后，白藜芦醇的 IC50 值分别为 18.7 μM 和 56.8 μM。白藜芦醇处理 B-CPAP 细胞可使 BRAF mRNA 水平降低 1.5 倍，ERK mRNA 水平降低 5.5 倍。NIS mRNA 水平增加了 3 倍。这项研究表明，白藜芦醇可抑制甲状腺乳头状癌细胞增殖，降低预后不良的 BRAF 和 ERK mRNA 及蛋白表达，同时增加 NIS mRNA 及蛋白表达，这表明白藜芦醇具有再分化作用。还需要更多的研究来评估白藜芦醇作为治疗甲状腺乳头状癌的新型疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pathology, research and practice 医学-病理学

CiteScore

5.00

自引率

3.60%

发文量

405

审稿时长

24 days

期刊介绍： Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.